Remdesivir Archives

0 Comments

Business, PharmaAlembic Pharmaceuticals, Net Revenue increases 17% to Rs 5393 crores, Pharma, Remdesivir

Alembic Pharmaceuticals Net Revenue increases 17% to Rs 5393 crores

Net Profit up 42% to Rs 1178 crores for the yearAlembic Pharmaceuticals Limited reported its consolidated financial results for the period ending 31st March 2021. Financial Highlights for the QuarterNet Sales for the quarter up 6% to Rs 1280 crores.Net Profit for the quarter up 12% to Rs 251 crores from Rs 225 crores. Financial Highlights for the YearNet sales for FY21 up 17% to Rs 5393 crores against Rs 4606 crores.Net profit for FY21 up 42% to Rs 1178 crores from Rs 829 crores. Mr. Pranav…

Jubilant Pharma develops a novel oral formulation of Remdesivir.

Jubilant Pharma on Monday announced that it has developed a novel oral formulation of Remdesivir, which, the company said, is likely to ease the capacity constraint that injectable formulation faces and ensure wider and timely availability for covid-19 patients. The development includes successful completion of safety and studies showing absorption of the oral formulation in bodies of animals and healthy human volunteers in India, the company said. Jubilant Pharma has sought authorisation for additional studies for the oral formulation from the Drug Controller General of India (DCGI)…

Prices of Ramdesivir slashed on orders of National Pharma authorities.

The National Pharmaceutical Pricing Authority under the Department of Pharmaceuticals declared change in prices for seven brands of Remdesivir injections of potency 100mg per vial Pharmaceutical companies manufacturing the anti-COVID medicine Remdesivir in India have voluntarily slashed prices following government intervention, National Pharmaceutical Pricing Authority under the Department of Pharmaceuticals announced on Saturday. The authority declared change in prices for seven brands of Remdesivir injections of potency 100mg per vial. After the price cuts, ranging from Rs 1,000 to Rs 2,700, Cadila Healthcare's Remdac continues to be…